|
|
Volumn 299, Issue 5605, 2003, Pages 333-335
|
|
Neuroscience: Deconstructing schizophrenia
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DISEASE CONTROL;
DRUG DOSAGE;
FAMILY STUDIES;
BIOMEDICAL ENGINEERING;
CATECHOL METHYLTRANSFERASE INHIBITOR;
DOPAMINE RECEPTOR AFFECTING AGENT;
NEUROLEPTIC AGENT;
NICOTINIC AGENT;
NICOTINIC RECEPTOR BLOCKING AGENT;
RISPERIDONE;
DRUG DEVELOPMENT;
NEUROLOGY;
AGITATION;
CLINICAL TRIAL;
COGNITIVE DEFECT;
DOPAMINERGIC SYSTEM;
DRUG EFFICACY;
DRUG LEGISLATION;
FAMILIAL DISEASE;
FAMILY STUDY;
GENE THERAPY;
GENETIC PREDISPOSITION;
HUMAN;
LOW DRUG DOSE;
MOLECULAR PROBE;
NEUROPATHOLOGY;
PHENOTYPE;
PRIORITY JOURNAL;
PROFESSIONAL STANDARD;
PSYCHOPHARMACOTHERAPY;
PSYCHOSIS;
SCHIZOPHRENIA;
SHORT SURVEY;
SIDE EFFECT;
TARDIVE DYSKINESIA;
AFRICAN CONTINENTAL ANCESTRY GROUP;
ATTENTION;
BRAIN;
CATECHOL O-METHYLTRANSFERASE;
COGNITION;
ENZYME INHIBITORS;
EUROPEAN CONTINENTAL ANCESTRY GROUP;
FAMILY;
HUMANS;
MEMORY;
NEUROPSYCHOLOGICAL TESTS;
NEUROTRANSMITTER AGENTS;
PHENOTYPE;
PSYCHOTROPIC DRUGS;
QUANTITATIVE TRAIT LOCI;
RECEPTORS, NICOTINIC;
SCHIZOPHRENIA;
SCHIZOPHRENIC PSYCHOLOGY;
|
|
EID: 0037449570
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.299.5605.333 Document Type: Short Survey |
|
Times cited : (48)
|
|
References (0)
|